Cambridge Healthtech Institute’s 5th Annual

EMERGING TARGETS FOR ONCOLOGY & BEYOND

Hitting the Bullseye

May 12-13, 2026

 

Cambridge Healthtech Institute's 5th annual Emerging Targets for Oncology & Beyond conference highlights the discovery and validation of promising new targets, as well as previously "undruggable” targets, showcasing advances in AI-driven discovery, target validation and degrader technologies. Discussions will cover innovative approaches for intracellular, excellular and glyco-epitope targeting. By bridging oncology with opportunities in autoimmune disease, inflammation and CNS disorders etc., this program offers a broad perspective on how target innovation is reshaping therapeutic pipelines across multiple indications.

 

Coverage will include, but is not limited to:

 

NOVEL TARGETS LANDSCAPE—SCREENING AND VALIDATION

  • B7H3, ROR1, SEZ6, CD123, IGSF8, CCR8 as emerging therapeutic targets
  • CLDN18.2, Nectin-4, PSMA, HER2 for solid tumors
  • Moving from CD8 to CD4 T cells, or NK cells
  • Latest targets beyond PD-1/PD-L1: LAG3 and others

TARGET DISCOVERY PLATFORMS USING AI AND OTHERS

  • Identify novel epitopes through post-translational modifications and glycotopes, misfolding etc.
  • AI/ML applications in target identification and patient stratification
  • Angiogenesis targeting for tumors

INTRACELLULAR TARGETING—INTERNALIZATION AND MECHANISMS

  • How to develop better internalization molecules
  • Cell-penetrating antibodies reaching cytoplasmic and nuclear targets
  • Antibody-based delivery of gene editing tools
  • Targeting previously "undruggable" intracellular proteins

PROTEIN DEGRADERS—INNOVATIVE APPROACH FOR UNDRUGGABLE TARGETS

  • Degraders as new payloads for ADCs with distinct MoAs and potential (e.g., PROTACs)
  • Degraders as intracellular biodegrader platforms via fusion to E3 ligases
  • Degraders as extracellular biodegraders through targeting of membrane-anchored E3 ligases.
  • Antibody-mediated protein degraders eg: LYTACs and AbTACs

 

TARGETS FOR AUTOIMMUNE DISEASES, INFLAMMATION, CNS, OTHER INDICATIONS

 

The deadline for priority consideration is October 17, 2025.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 


For more details on the conference, please contact:

Mimi Langley

Executive Director, Conferences

Cambridge Healthtech Institute

Email: mlangley@healthtech.com

 

For sponsorship information, please contact:

Companies A-K

Jason Gerardi

Sr. Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-5452

Email: jgerardi@healthtech.com

 

Companies L-Z

Ashley Parsons

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-1340

Email: ashleyparsons@healthtech.com


Register

View By:


Premier Sponsors

FairJourneyBiologics GenScript-CRO Integral-Molecular_NEW   Nona_Biosciences_NEW